Today, John Cumbers talks with Ursheet Parikh, a general partner at Mayfield Fund, an early-stage, global venture capital firm with a people-first philosophy and a 50-plus-year history of investing and partnering with founders. John and Ursheet will discuss the state of the synthetic biology market and what startups can do to survive and thrive in this turbulent economy.

Ursheet Parikh is a general partner at Mayfield Fund, where he has been investing in both human and planetary health companies since 2013. Ursheet’s investments include companies such as Mammoth Biosciences, which has a focus on discovering novel CRISPR systems; Mission Bio, which is looking to apply a Single-Cell Sequencing platform toward oncology; Qventus, which is blazing a trail in Healthcare-AI; and Endpoint Health, which is reshaping the Precision Immunology space—just to name a few. Ursheet holds an MBA from the Wharton School and a Bachelors in Computer Science from the Indian Institute of Technology in Mumbai. He is passionate about accelerating healthcare innovation and transforming college education, where his family foundation is focused.

Connect with Ursheet: @ursheet

Connect with John: @johncumbers

Stay updated on the latest news in synthetic biology, check out our weekly newsletter and follow us on social media:

Twitter | LinkedIn | Facebook

Be sure you make it to our SynBioBeta events! Click here for more information.